Get Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Somewhat Positive Press Coverage Somewhat Unlikely to Affect Cipher Pharmaceuticals (NASDAQ:CPHR) Stock Price

Media headlines about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) have been trending somewhat positive on Monday, Accern Sentiment reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cipher Pharmaceuticals earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.4446637112034 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Get Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Cipher Pharmaceuticals (NASDAQ:CPHR) remained flat at $2.99 during mid-day trading on Monday. Cipher Pharmaceuticals has a 12-month low of $2.55 and a 12-month high of $5.25. The firm has a 50-day moving average price of $2.99 and a 200-day moving average price of $2.99.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was posted by [[site]] and is the sole property of of [[site]]. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at [[permalink]].

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.